<DOC>
	<DOCNO>NCT00692952</DOCNO>
	<brief_summary>A multicentric clinical trial three Chinese Maternal Child Hospitals conduct evaluate efficacy , safety acceptability newly-developed vaginal contraceptive gel , optimized benzalkonium chloride ( BZK ) gel contain 18mg BZK , comparison currently market ( China ) contraceptive gel LELEMIÂ® contain 50mg Nonoxynol-9 ( N-9 ) .</brief_summary>
	<brief_title>Effectiveness BenZalkonium Chloride Gel Vaginal Contraceptive : Multicentric Randomized Controlled Trial</brief_title>
	<detailed_description>A phase II , multicentric , randomize , control clinical trial .</detailed_description>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Nonoxynol</mesh_term>
	<mesh_term>Benzalkonium Compounds</mesh_term>
	<criteria>risk pregnancy desire contraception regular menstrual cycle ( 2135 day ) low risk HIV sexually transmit infection sexually active use test product primary method contraception keep diary coital activity , product use , adverse event diagnosis vaginal infection symptom STDs baseline know allergy hypersensitivity N9 BZK menopause one month breastfeed vaginal bleed unknown reason genitourinary system anomaly hysteroptosis II severe cystocele moderate severe erosion cervix malignant reproductive system tumor</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>contraceptive efficacy</keyword>
</DOC>